( c ) Body weight time course, ( d ) change in body weight, fat mass (FM), and fat free mass (FFM) from day 5 to day 21
The second, semaglutide at the 2.4 mg dose, is the GLP-1 receptor agonist already established for weight management
Observed Effects of BPC-157 in Preclinical Healing Studies In laboratory and animal studies, BPC-157 has demonstrated a wide range of biological activities that may support healing and tissue regeneration
The rationale for blending these two peptides stems from their non-overlapping receptor targets and complementary metabolic effects: Amylin Pathway (Cagrilintide): Targets amylin receptors in the brainstem Creates meal-specific satiety signals Slows gastric emptying through distinct mechanisms Reduces meal size and eating frequency Triple Agonist Pathway (Retatrutide): Activates GIP, GLP-1, and glucagon receptors Enhances insulin secretion and glucose metabolism Increases energy expenditure through glucagon effects Provides broader metabolic regulation When combined, these pathways could theoretically provide additive or synergistic effects on weight management and metabolic function
Our licensed physicians will take numerous factors into consideration when finding the right option for you
